Table 1.

ANO7 expression and prostate cancer phenotype

Parameter	n	Fraction of ANO7 expression (%)				P
		Negative	Weak	Moderate	Strong
All cancers	13,594	7.6	9.3	48.7	34.4
Tumor stage						< 0.0001
pT2	8889	5.5	7.0	47.4	40.2
pT3a	2984	9.8	11.0	52.1	27.1
pT3b-pT4	1668	14.5	18.5	49.6	17.3
Gleason grade						< 0.0001
≤ 3+3	2730	4.9	5.6	46.2	43.3
3+4	7372	5.3	7.7	49.8	37.3
3+4 Tert.5	614	7.5	12.2	47.4	32.9
4+3	1292	14.5	12.8	49.6	23.1
4+3 Tert.5	898	13.0	18.3	50.8	17.9
≥ 4+4	591	24.0	18.8	44.8	12.4
Quantitative Gleason grade
≤ 3+3	2730	4.9	5.6	46.2	43.3	< 0.0001
3+4 ≤ 5%	1927	3.9	5.3	46.4	44.4
3+4 (6%–10%)	1845	4.3	6.0	50.4	39.3
3+4 (11%–20%)	1614	4.8	7.7	51.4	36.1
3+4 (21%–30%)	813	6.8	11.6	51.4	30.3
3+4 (31%–49%)	663	8.9	8.9	53.4	28.8
3+4 Tert.5	614	7.5	12.2	47.4	32.9
4+3 (50%–60%)	556	9.9	10.4	50.0	29.7
4+3 Tert.5	898	13.0	18.3	50.8	17.9
4+3 ≥ 61%	559	17.4	12.9	50.8	19.0
≥ 4+4	511	23.3	17.0	46.8	12.9
Lymph node metastasis						< 0.0001
N0	8150	7.9	9.7	48.9	33.4
N+	864	17.4	19.9	45.7	17.0
Preoperative PSA level (ng/mL)						< 0.0001
< 4	1657	8.8	8.6	49.3	33.3
4–10	8140	6.3	8.3	48.2	37.2
10–20	2817	8.9	10.7	49.7	30.6
> 20	898	12.6	15.0	48.6	23.8
Surgical margin						< 0.0001
Negative	10,922	6.9	8.5	48.5	36.0
Positive	2624	10.1	12.5	49.4	28.0

ANO7, anoctamin 7; PSA, prostate-specific antigen.